Myriam Decaussin-Petrucci

[Miscellaneous benign lesions of the bladder and the urinary tract].

Molecular profile of hyalinizing trabecular tumours of the thyroid: high prevalence of RET/PTC rearrangements and absence of B-raf and N-ras point mutations.

Prevalence of differentiated thyroid cancer in 810 cases of surgically treated goiter in Yemen.

Association between sarcoidosis and testicular carcinoma: a diagnostic pitfall.

[A rare testicular tumor].

Thyroid cancer: is the incidence rise abating?

[Isolated testicular mass revealing a metastasis of prostate adenocarcinoma].

Nonconventional papillary thyroid carcinomas with pleomorphic tumor giant cells: a diagnostic pitfall with anaplastic carcinoma.

Thyroglobulin measurement in fine-needle aspirates of lymph nodes in patients with differentiated thyroid cancer: a simple definition of the threshold value, with emphasis on potential pitfalls of the method.

Urinary PCA3 score predicts prostate cancer multifocality.

[Atypical urothelial cells (AUC): A Bethesda-derived wording applicable to urinary cytopathology].

[Value of PCA3 urinary test for prostate biopsy decision: the Lyon-Sud University Hospital experience].

TM4SF1, a novel primary androgen receptor target gene over-expressed in human prostate cancer and involved in cell migration.

Oncogenic alterations in papillary thyroid cancers of young patients.

Detection of BRAF V600E mutation in thyroid fine-needle aspiration specimens by High Resolution Melting (HRM) analysis.

Let-7a down-regulation plays a role in thyroid neoplasias of follicular histotype affecting cell adhesion and migration through its ability to target the FXYD5 (Dysadherin) gene.

Thyroid cancers in children, adolescents, and young adults with and without a history of childhood exposure to therapeutic radiation for other cancers.

Immunohistochemical markers in the diagnosis of papillary thyroid carcinomas: The promising role of combined immunostaining using HBME-1 and CD56.

PCA3 and PCA3-based nomograms improve diagnostic accuracy in patients undergoing first prostate biopsy.